OncLive | Obinutuzumab Regimen Slows CLL Compared With Standard Therapy OncLive Patients with chronic lymphocytic leukemia (CLL) and major comorbidities had significantly better outcomes when treated with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) instead of rituximab (Rituxan), a randomized trial showed. The addition ... |
